InflaRx (IFRX) AI Stock Analysis

• Market Cap: $111.44M
• Dividend Yield: N/A
• Average Volume (3M): 283.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: 178.84%
• EPS Growth: -40.60%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 67,133,270
• 10 Day Avg. Volume: 244,796
• 30 Day Avg. Volume: 283,936
• PEG Ratio: -0.42
• Price to Book (P/B): 1.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.67
• Price Target Upside: 422.29% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

InflaRx's overall stock score is low, primarily due to significant financial challenges, including ongoing losses and cash flow issues. While short-term technical indicators suggest some upward momentum, the overbought signals and poor valuation metrics temper optimism. Investors should be cautious due to the company's persistent operational struggles and lack of profitability.

Positive Factors

Clinical Studies

INF904 has completed sub-chronic and chronic toxicology studies with no safety signals identified, supporting the potential for longer-term dosing.

Drug Development

INF904 is potentially a better C5aR inhibitor than FDA-approved Tavneos, with improved PK/PD data.

Market Opportunities

Both CSU and HS are meaningful commercial opportunities.

Negative Factors

Regulatory Challenges

PG has no approved drugs in Europe or in the U.S., indicating regulatory challenges despite the market opportunity.

Uncertainty in Results

Analyst is currently on the sideline for INF904 in CSU and HS without first seeing the clinical data.

InflaRx Business Overview & Revenue Model

Company Description

InflaRx (IFRX) is a clinical-stage biopharmaceutical company focused on discovering and developing anti-inflammatory therapeutics by targeting the complement system. The company's core product, vilobelimab, is a monoclonal anti-C5a antibody that aims to treat a variety of inflammatory conditions and autoimmune diseases. InflaRx operates primarily in the biotechnology and pharmaceutical sectors, striving to provide innovative treatment options for patients suffering from severe and life-threatening inflammatory diseases.

How the Company Makes Money

InflaRx generates revenue primarily through partnerships and collaboration agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on development and regulatory achievements, and royalties on sales if products reach commercialization. Additionally, InflaRx may receive research and development grants or funding from governmental or non-governmental organizations to support its clinical trials and drug development programs. The company's revenue model is heavily dependent on the successful clinical development and eventual commercialization of its lead product candidate, vilobelimab, as well as potential future products.

InflaRx Financial Statement Overview

Summary

InflaRx's financial performance is weak, with significant challenges in profitability and cash flow management. The company is operating at a loss with negative margins and consistent cash outflows. Although the balance sheet shows limited leverage, the negative return on equity and persistent losses raise concerns for future financial stability.

Income Statement

InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.

Balance Sheet

The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.

Cash Flow

InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
129.75K	165.79K	63.09K	0.00	0.00	0.00
	Gross Profit
-2.98M	-3.15M	-469.17K	-585.85K	-696.14K	-664.03K
	EBIT
-53.53M	-53.01M	-44.91M	-32.24M	-47.63M	-33.94M
	EBITDA
-45.87M	-45.55M	-42.06M	-31.29M	-46.90M	-32.47M
	Net Income Common Stockholders
-44.72M	-46.06M	-42.67M	-27.04M	-45.65M	-34.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
65.86M	52.84M	90.27M	81.81M	83.41M	81.13M
	Total Assets
87.00M	76.02M	120.21M	102.40M	125.14M	88.22M
	Total Debt
702.63K	805.09K	1.12M	1.36M	1.43M	559.04K
	Net Debt
-46.58M	-17.57M	-11.65M	-14.91M	-24.82M	-25.41M
	Total Liabilities
16.53M	14.60M	17.63M	14.05M	19.86M	10.35M
	Stockholders Equity
70.47M	61.42M	102.67M	88.35M	105.28M	77.86M
Cash Flow		Free Cash Flow
-47.75M	-48.60M	-37.89M	-33.91M	-39.97M	-36.62M
	Operating Cash Flow
-47.70M	-48.56M	-37.81M	-33.74M	-39.94M	-36.53M
	Investing Cash Flow
43.08M	52.36M	-17.70M	19.36M	-25.95M	21.36M
	Financing Cash Flow
27.48M	386.45K	52.99M	1.94M	61.58M	9.17M

InflaRx Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.66
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Neutral. The current price of 1.66 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.29, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 57.08 is Neutral, neither overbought nor oversold. The STOCH value of 68.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IFRX.

InflaRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%
IFRX	40 Underperform	$111.44M	―	-62.38%	―	178.84%	-40.60%
CABA	39 Underperform	$103.01M	―	-73.85%	―	―	-40.59%
VTGN	39 Underperform	$71.00M	―	-46.28%	―	-33.00%	54.91%
CLSD	38 Underperform	$68.30M	―	91.63%	―	-55.47%	24.92%
JSPR	35 Underperform	$74.06M	―	-101.34%	―	―	21.40%